HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Last Updated on: May 25, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1229 as of 23 May 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 428.84 crore as compare to the Dec '24 revenue of ₹ 399.28 crore. This represent the growth of 7.4%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 184.72 crore as compare to the Dec '24 ebitda of ₹ 48.08 crore. This represent the growth of 284.19%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -107 crore to ₹ 98.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About OneSource Specialty Pharma Ltd

  • Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
  • The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
  • The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
  • Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

Dr Reddys Laboratories Ltd News Hub

News

DRL's USA facility gets 2 observations from USFDA

The USFDA completed aforementioned inspection and issued form-483 with two observations. H...

Read more

19 May 2025 08:32

News

USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York

Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA)...

Read more

17 May 2025 11:32

News

Dr Reddys Lab jumps after Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

12 May 2025 14:50

News

Dr Reddys Laboratories AGM scheduled

Dr Reddys Laboratories announced that the 41th Annual General Meeting(AGM) of the company ...

Read more

10 May 2025 10:17

News

Dr Reddys Lab Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

10 May 2025 10:52

News

Board of Dr Reddys Laboratories recommends Final Dividend

Dr Reddys Laboratories announced that the Board of Directors of the Company at its meeting...

Read more

09 May 2025 17:01

OneSource Specialty Pharma Ltd News Hub

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

30 Apr 2025 11:35

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

25 Jan 2025 10:23

News

Shares of Onesource Specialty Pharma list in T Group

The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective ...

Read more

24 Jan 2025 09:22

SWOT Analysis Of OneSource Specialty Pharma Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or OneSource Specialty Pharma Ltd?

Market cap of Dr Reddys Laboratories Ltd is 102,617 Cr while Market cap of OneSource Specialty Pharma Ltd is 19,319 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd?

As of May 25, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1229.75. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1688.2.

How do dividend payouts of Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions